SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.04
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.79

30 Apr
2026

0.010

OPEN

$2.76

0.36%

HIGH

$2.80

9,059,335

LOW

$2.76

TARGET
$3.216 15.3% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 5.1 6.3 xxx
DPS (cps) xxx 1.8 4.1 xxx
EPS Growth xxx 100.0% 24.5% xxx
DPS Growth xxx 82.7% 100.0% xxx
PE Ratio xxx N/A 44.6 xxx
Dividend Yield xxx N/A 1.5% xxx
Div Pay Ratio(%) xxx 35.6% 65.1% xxx

Dividend yield today if purchased 3 years ago: 2.59%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.64

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx5.1
DPS All xxxxxxxxxxxxxxx1.8
Sales/Revenue xxxxxxxxxxxxxxx14,404.4 M
Book Value Per Share xxxxxxxxxxxxxxx40.6
Net Operating Cash Flow xxxxxxxxxxxxxxx598.8 M
Net Profit Margin xxxxxxxxxxxxxxx8.83 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-
Return on Invested Capital xxxxxxxxxxxxxxx-
Return on Assets xxxxxxxxxxxxxxx-
Return on Equity xxxxxxxxxxxxxxx-
Return on Total Capital xxxxxxxxxxxxxxx-
Free Cash Flow ex dividends xxxxxxxxxxxxxxx60.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx194 M
Long Term Debt xxxxxxxxxxxxxxx1,877 M
Total Debt xxxxxxxxxxxxxxx2,071 M
Goodwill - Gross xxxxxxxxxxxxxxx3,617 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx139 M
Price To Book Value xxxxxxxxxxxxxxx7.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx57.6 M
Capex % of Sales xxxxxxxxxxxxxxx0.40 %
Cost of Goods Sold xxxxxxxxxxxxxxx10,948 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,606 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx80 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxxxxxx xx xxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

27/02/2026

3

Hold

$3.00

7.53%

Key numbers in Sigma Healthcare's 1H26 were comfortably ahead of consensus and Bell Potter's forecast. Revenues up 15% year on year and earnings up 18.3% have been identified as the highlights.

Growth is expected to ease from this point as the group begins to cycle GLP-1 sales in the prior period. Growing the domestic store footprint remains difficult, Bell Potter notes.

The group expects to add 24 new franchisees domestically in 2H26 but commentary counters the key will be how many it loses along the way and the net adjustment to the network footprint.

Meanwhile, Sigma is only part way through its cost out program. Hold and $3.00 target retained.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 4.60 cents and EPS of 6.60 cents.
Bell Potter forecasts a full year FY27 dividend of 5.20 cents and EPS of 7.50 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

28/04/2026

1

Buy

$3.60

29.03%

Jarden highlights Amazon's accelerating scale in Australia, estimating 2025 gross merchandise value (GMV) at around $9.6bn, up 30% yoy, driven by third-party sellers, Prime growth and higher shopping frequency.

The company is now a major force in non-food retail, with growing penetration across electronics, grocery and hardware, supported by continued investment in logistics, range and delivery speed.

This expansion is expected to intensify competitive pressure, increasing risks to sales, margins and capital requirements for incumbents, the analysts caution.

Jarden favours defensive growth names such as Woolworths Group, Coles Group, Sigma Healthcare and Metcash, alongside exposure to the tech and AI cycle via JB Hi-Fi and structural growers such as Sigma.

For Sigma Healthcare, the analysts have a Buy rating and $3.60 target.

FORECAST
Jarden forecasts a full year FY26 dividend of 3.80 cents and EPS of 6.40 cents.
Jarden forecasts a full year FY27 dividend of 4.60 cents and EPS of 7.70 cents.
Access Extra Coverage Research History >

SIG STOCK CHART

FNArena News on SIG

Latest Health & Nutrition News

1
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
2
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
3
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
4
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
5
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
6
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
7
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia
8
Blackmores: Hopes Pinned On Restructuring

Nov 01 2019 - Australia
9
Blackmores Peps Up Its Strategy For China

Apr 17 2019 - Australia
10
API/Sigma Merger Plan Rears, Again

Dec 17 2018 - Australia